March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction
Fund in Europe leads investment to progress commercialization of breakthrough gelsolin therapy to treat inflammatory and infectious diseases. NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the completion of a […]